TY - JOUR A1 - Rhim, Ha-Young A1 - Won, Sae-Yeon A1 - Kashefiolasl, Sepide A1 - Brawanski, Nina A1 - Hattingen, Elke A1 - Berkefeld, Joachim A1 - Seifert, Volker A1 - Konczalla, Jürgen T1 - Multidrug-resistant organisms (MDROs) in patients with subarachnoid hemorrhage (SAH) T2 - Scientific reports N2 - Patient care in a neurointensive care unit (neuro-ICU) is challenging. Multidrug-resistant organisms (MDROs) are increasingly common in the routine clinical practice. We evaluated the impact of infection with MDROs on outcomes in patients with subarachnoid hemorrhage (SAH). A single-center retrospective analysis of SAH cases involving patients treated in the neuro-ICU was performed. The outcome was assessed 6 months after SAH using the modified Rankin Scale [mRS, favorable (0–2) and unfavorable (3–6)]. Data were compared by matched-pair analysis. Patient characteristics were well matched in the MDRO (n = 61) and control (n = 61) groups. In this center, one nurse was assigned to a two-bed room. If a MDRO was detected, the patient was isolated, and the nurse was assigned to the patient infected with the MDRO. In the MDRO group, 29 patients (48%) had a favorable outcome, while 25 patients (41%) in the control group had a favorable outcome; the difference was not significant (p > 0.05). Independent prognostic factors for unfavorable outcomes were worse status at admission (OR = 3.1), concomitant intracerebral hematoma (ICH) (OR = 3.7), and delayed cerebral ischemia (DCI) (OR = 6.8). Infection with MRDOs did not have a negative impact on the outcome in SAH patients. Slightly better outcomes were observed in SAH patients infected with MDROs, suggesting the benefit of individual care. KW - Health care KW - Medical research KW - Neurology Y1 - 2021 UR - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/63711 UR - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-637114 SN - 2045-2322 N1 - Open Access funding enabled and organized by Projekt DEAL. VL - 11 IS - art. 8309 SP - 1 EP - 7 PB - Macmillan Publishers Limited, part of Springer Nature CY - [London] ER -